#### The Impact of Normal Aging Out on Continuity of Treatment among Children and Adolescents Living with HIV in the PEPFAR Supported Program in Kenya

Authors: Lydia Odero<sup>1\*</sup>, Aaron Chafetz<sup>2</sup>, Mary Gikura<sup>3</sup>, Deborah Goldstein<sup>2</sup>, Rachel Golin<sup>2</sup>, Diana Kemunto<sup>1</sup>, Nelly Maina<sup>4</sup>, Immaculate Mutisya<sup>5</sup>, Kennedy Muthoka<sup>3</sup>, Evelyn Nganga<sup>1</sup>, Tishina Okegbe<sup>4</sup>, Salome Okutoyi<sup>1</sup>, Gonza Omoro<sup>6</sup>, George Siberry<sup>2</sup>, Rose Wafula<sup>7</sup>, Dunstan Achwoka<sup>1</sup>

<sup>1</sup>United States Agency for International Development (USAID), Nairobi, Kenya

<sup>2</sup> Office of HIV/AIDS, United States Agency for International Development (USAID), Washington, DC, USA

<sup>3</sup> Palladium Kenya, Nairobi, Kenya

<sup>4</sup>GHTASC, Credence Management Solutions LLC, supporting United States Agency for International Development (USAID), Office of HIV/AIDS, Washington, DC, USA

<sup>5</sup>U.S. Centres for Disease Control (CDC), Nairobi, Kenya

<sup>6</sup>U.S. Department of Defense, Nairobi, Kenya

<sup>7</sup>National AIDS and STI Control Programme (NASCOP), Nairobi, Kenya

\*Corresponding author Email: <u>lodero@usaid.gov</u> (LO)

# 1 Abstract

Introduction: To reduce HIV-related morbidity and mortality among children and adolescents living with HIV, defined as those 0-14 years old, continuity of treatment is critical. Treatment continuity estimates among children and adolescents living with HIV lag adults. We sought to understand how aging out among children and adolescents living with HIV in Kenya impacts continuity of treatment.

7

8 Methods: A retrospective cohort analysis was performed on de-identified individual-level data 9 from the Kenya National Data Warehouse for all clients who initiated and/or received antiretroviral 10 therapy between the periods of Oct 1, 2018 and Sep 30, 2022 (US Government fiscal years 2019-11 2022). Children and adolescents living with HIV previously on antiretroviral therapy and those 12 newly initiating antiretroviral therapy were included in the analysis. Outcomes included aging out 13 of the cohort after turning 15 years old, interruption in treatment, return to treatment, and remaining 14 active on treatment.

15

16 **Results:** The study analyzed client-level data for four US Government fiscal years 2019-2022. 17 The number of active children and adolescents living with HIV on treatment at the end of fiscal 18 year 2019 was 44,628. This changed to 48,218, 48,262, and 44,780 representing 8%, 0%, and -7% 19 cohort growth/loss at the end of fiscal years 2020, 2021 and 2022, respectively. Among those who were on treatment at the beginning of each fiscal year, aging-out accounted for 47%, 39%, and 20 21 28% of the total losses for the periods 2020, 2021 and 2022, respectively. Interruptions in treatment accounted for proportions ranging from 5-9% among those active on treatment. Among the newly-22 23 initiated on treatment within each fiscal year, aging-out proportions ranged from 3%-5%. Among

those who returned to treatment in each fiscal year, the proportions who remained active at the end
of the fiscal year varied from 72%-76%.

26

Conclusions: This analysis suggests that normal aging-out results in underestimation of HIV
treatment continuity for children and adolescents living with HIV. Routine aging out analyses can
inform programs on their true rates of interruptions in treatment, as they work to achieve epidemic
control among children and adolescents living with HIV.

31

32 Key words: Adolescents, Aging-out, HIV, HIV care continuum, Care and Treatment, Pediatrics

## 33 Introduction

34 Despite the "Treat All" era, pediatric antiretroviral therapy (ART) coverage remains well-below 35 adult coverage, with 63% ART coverage rates for children and adolescents living with HIV (C/ALHIV) (0-14 years) in Eastern and Southern Africa compared to 83% for adults ( $\geq$ 15 years) 36 [1]. Only 70% of C/ALHIV in the region have a known HIV status, and of those receiving ART, 37 only 51% are virally suppressed [2]. These dire statistics are attributed in part to inadequate 38 39 antenatal care to prevent vertical transmission, poor retention in care among pregnant women with 40 HIV, and the rate of HIV infection among children while breastfeeding [3]. Poor viral load suppression (VLS) and interruptions in treatment (IIT) among C/ALHIV has been associated with 41 42 among others, difficult to take ART formulations; history of opportunistic infections; and 43 caregiver's VLS status and household vulnerability [4-8].

44

45 Optimized case-finding and enhanced linkage to treatment are needed to close gaps in ART 46 coverage and HIV-related morbidity and mortality for C/ALHIV [9]. While HIV continuity of 47 treatment (CoT) is essential for VLS, prevention of disease progression and mortality, and further 48 transmission; data is limited on impact of aging on CoT proxies used for programmatic evaluation 49 and improvement.

50

Tanzanian program data revealed substantial loss in the number of C/ALHIV on ART in 2015.
Subsequently, systematic retrospective analysis led to development of a standardized tool for loss
analyses for those aged 0-14 years (unpublished program data). This tool was refined in 2019,
when the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) instituted IIT reporting.
Included were C/ALHIV who had: - transferred out of a clinical site; refused or stopped ART;
experienced IIT; and died [10]. These site-level data provided granular assessment of C/ALHIV
experiencing IIT and were used to optimize CoT and achieve VLS.

58

In 2021, PEPFAR advised programs to routinely review adolescent fine age bands to identify ongoing gaps in CoT and VLS [11]. Since 2022, PEPFAR guidance has encouraged programs to evaluate electronic medical records (EMRs) and person-based registries to assess actual experience of aging out in pediatric cohorts [12-13]. However, because PEPFAR's data is reported at aggregate and not individual-level, analysis of CoT follows the same and does not correctly account for clients who 'age out' during transitions between fiscal years (FY).

65

Analysis of PEPFAR data from 2018-2019 in eight African countries showed that aging can distort
age-band retention estimates [14]. This study used 1-year age-bands from 2018 SPECTRUM

68 modeling data to adjust for aging and reported that the adjustment increased ART retention 69 estimates for those aged <1 and 1-9 years but had variable effects on retention for 10-14 and 15-70 19 years. Authors recommended country-specific analysis to better understand implications of 71 'aging out' for these age bands and better optimize C/ALHIV CoT [14]. In Tanzania, the USAID 72 Afya Yangu Northern project reported that in FY2022, aging out contributed to 48% of the loss in 73 current on ART among C/ALHIV and adjustment for aging out improved pediatric proxy retention 74 from 86% to 96% and program growth from -2% to 10% (unpublished data). Additionally, retrospective cohort analysis of C/ALHIV on ART in Kenyan USAID-supported facilities from 75 76 2019-2020 showed that normal aging results in underestimated CoT rates [15]. 77

Compared to aggregate-level data, individual-level data presents a better platform to describe the aging effect among clients on treatment. Evolution of EMRs and establishment of the Kenya National Data Warehouse (NDW) provides such an opportunity [16]. This analysis utilizes individual-level data from the NDW to understand how C/ALHIV aging-out impacts CoT in Kenya.

### 83 Methods

### 84 Study Design

The study employed a retrospective cohort observational design to investigate aging out and treatment interruptions among C/ALHIV on treatment. The analysis included all clients 0-14 years old at any time period between October 1, 2018, and September 30, 2022 [FY2019 – FY2022)] and were either newly initiated on ART or currently on ART during the same period.

89

### 90 Materials or Instruments & Data Collection

91 De-identified client records were accessed from the National Data Warehouse (NDW) on April 92 18, 2023, and extracted for analysis. NDW is a repository of de-identified individual-level client data offered care and treatment services at health facilities. Facility-based health-care workers use 93 94 the Ministry of Health comprehensive care clinic card (MOH 257) to document clinical notes for clients either newly initiating ART or attending subsequent clinical visits. This tool/card is 95 96 digitized in the facility EMR system. De-identified data from the facility EMR is then transmitted 97 to the NDW monthly. The authors did not have information that could identify individual clients during or after data collection. RStudio version 2022.12.0 was used for the analysis. 98

#### 99 Variables

Data were extracted from the NDW using the following variables: facility name, master facility listing code, client ID, date of birth, sex, ART initiation date, ART regimen at initiation, current ART regimen, appointment and visit dates. Using client's appointment and visit dates, the outcomes below were computed per FY:

104 1) Aged out - a client who turns 15 years old before or at the end of FY.

105 2) IIT - a client with no clinical contact for 28 days after their last scheduled appointment or
 106 expected clinical contact.

107 3) Return to treatment - a client who experienced IIT during any previous FYs, who
108 successfully reinitiated ART within the FY of interest and remained on treatment until the
109 end of that FY.

4) Active on treatment - a client who is currently receiving ART within a FY and remainedon ART as at the end of the FY.

112 5) Unclassified - a category for clients who do not fit into any of the defined categories113 mentioned above.

#### 114 Data Analysis

Data analysis involved a multi-step approach to longitudinal data on clients' status across multiple FYs with data cleaning and quality control procedures to eliminate irrelevant or incomplete records. The dataset was then grouped according to client identifiers and FYs; and aggregation techniques were employed to calculate counts of clients into various outcome categories for each FY. Descriptive techniques were used to summarize and present the data's key features. A Sankey diagram was used to present visualization of clients' movement from one outcome category at the beginning or in the course of a given FY to another category at the end of the same FY.

### 122 Ethical Considerations

The research was approved by Jomo Kenyatta University of Agriculture and Technology, Ethics and Research Committee (JKU/ISERC/02316/0880); Office of the Associate Director for Science, Centers for Disease Control and Prevention (CDC) with Accession #: CGH-KEN-1/18/23-8faf7; and research license obtained from the National Commission for Science, Technology & Innovation (NACOSTI/P/23/27455). Client's consent was not required as the authors neither interacted with the clients nor had access to identifiable data.

## 129 **Results**

Clinical records of C/ALHIV on treatment or initiating treatment in the Kenyan NDW were
analyzed for a period of four FYs 2019-2022. At the end of FY2019, 44,628 (72.7%) C/ALHIV

- 132 remained on treatment. At the end of each of the FYs 2020, 2021, and 2022, 48,218 (78.6%),
- 133 48,262 (78.7%) and 44,780 (73.0%) C/ALHIV remained active on treatment (Table 1).

Table 1: Kenya Children and Adolescent HIV Treatment Cohort, National DataWarehouse, Fiscal Years (FY) 2020 - 2022

	FY2020	FY2021	FY2022
	(n= 61,357)	(n=60,610)	(n=55,166)
Status During Fiscal Year			
Newly initiating ART	5,183 (8.4%)	3,264 (5.4%)	2,047 (3.7%)
Returned to Treatment	3,841 (6.3%)	3,191 (5.3%)	2,118 (3.8%)
Unclassified	7,705 (12.6%)	5,942 (9.8%)	2,752 (5.0%)
Current on Treatment (prior			
fiscal year)	44,628 (72.7%)	48,213 (79.5%)	48,249 (87.5%)
Status End of Fiscal Year			
Active on Treatment	48,218 (78.6%)	48,262 (78.7%)	44,780 (73.0%)
Interruptions in Treatment	6,903 (11.3%)	5,430 (8.8%)	3,400 (5.5%)
Aged Out	5,603 (9.1%)	6,734 (11.0%)	6,986 (11.4%)
Unclassified	633 (1.0%)	184 (0.3%)	- (0.0%)
Loss/Gain (%)	3,590(8%)	49(0%)	-3,469 (-7%)

134

Overall, the cohort grew by 3,590 (8%) in FY2020 and reduced by 3,469 (7%) by the end of FY 2022. C/ALHIV who had disengaged from care and returned to treatment captured within the course of FYs 2020, 2021, and 2022 stood at 3,841 (6.3%), 3,191 (5.3%), and 2,118 (3.8%) respectively. The cohort of C/ALHIV interrupting treatment at the end of FY2020, FY2021 and FY2022 were 6,903 (11.3%), 5,430 (8.8%) and 3,400 (5.5%) while 5,603 (9.1%), 6,734 (11.0%) and 6,986 (11.4%) C/ALHIV aged out at the end of each of the respective FYs (Table 1).

141

142	Over the four FYs from 2019-2022, 80% of C/ALHIV remained active on treatment among the
143	current on treatment cohort (i.e. those who were already on treatment at the start of the FY). For
144	this cohort, IIT stood at 4,187 (9%), 3,864 (8%), and 2,564 (5%) at the end of each of the three FY
145	transitions. In FY2020, 4,698 (11%) of the current on treatment cohort aged out, while in FY2021
146	and FY2022, 5,944 (12%) and 6,489 (13%) of the cohort aged out. IIT accounted for 53%, 61%
147	and 72% of the total losses experienced in FY2020, FY2021 and FY2022 respectively. Losses
148	attributed to aging out among clients currently on treatment were 47% in FY2020, 39% in FY21,
149	and 28% in FY2022 (Table 2).

 Table 2: Kenya C/ALHIV Aging Out Analysis (at end of FY2020, 2021 and 2022)

	FY2020	FY2021	FY2022
Among Active on Treatment (prior fiscal year)	(n= 44,628)	(n= 48,213)	(n= 48,249)
Remained Active on Treatment (%)	35,743 (80%)	38,405 (80%)	39,196 (81%)
Interruptions in Treatment (IIT) (%)	4,187 (9%)	3,864 (8%)	2,564 (5%)
Aged Out (%)	4,698 (11%)	5,944 (12%)	6,489 (13%)
% Loss attributed to aging out	47%	39%	28%
% Loss attributed to IIT	53%	61%	72%
Among Clients Newly Initiated on Treatment			
(current fiscal year)	(n= 5,183)	(n= 3,264)	(n=2,047)
Remained Active on Treatment (%)	3,353 (65%)	2,534 (78%)	1,721 (84%)
Interruptions in Treatment (IIT) (%)	1,048 (20%)	429 (13%)	233 (11%)
Aged Out (%)	149 (3%)	117 (4%)	93 (5%)
Unclassified	633	184	
Returned to Treatment	(n=3,841)	(n=3,191)	(n=2,118)

Remained Active on Treatment (%)	2,904 (76%)	2,294 (72%)	1,575 (74%)
Interruptions in Treatment (IIT) (%)	647 (17%)	646 (20%)	352 (17%)
Aged Out (%)	290 (8%)	251 (8%)	191 (9%)

150

151 Among C/ALHIV who newly initiated ART, 3,353 (65%), 2,534 (78%), and 1,721 (84%) 152 remained active across the three FY transitions into FY2020, FY2021, and FY2022, respectively. 153 IIT in this cohort stood at 1,048 (20%), 429 (13%), and 233 (11%) across the three FYs. Aging 154 out among C/ALHIV who newly initiated ART consisted of 149 (3%), 117 (4%) and 93 (5%) 155 clients across the three FY transitions. 156 Among the cohort of C/ALHIV who returned to treatment, those who remained active till end of 157 158 the FY consisted of 2,904 (76%), 2,294 (72%) and 1,575 (74%) across FY2020, FY2021 and 159 FY2022 respectively. IIT were 647 (17%), 646 (20%), 352 (17%) while aging out was 290 (8%), 160 251 (8%) and 191 (9%) for the three FYs (Table 2). 161 162 In 2020, 7,705 clients were in the unclassified category, making up 8% of the total. However, by 163 the end of 2020, this number dropped to 633 (92% decrease). 164 165 The movement of clients from one category to the other between fiscal years is depicted by the 166 Sankey diagrams as shown in Figs 1-3. 167 168 Fig 1. Tracking treatment outcomes among C/ALHIV in Kenya – FY2019 - FY2020 169 Fig 2. Tracking treatment outcomes among C/ALHIV in Kenya – FY2020 - FY2021 170 Fig 3. Tracking treatment outcomes among C/ALHIV in Kenya – FY2021 - FY2022

# 171 **Discussion**

172 Normal aging-out of the <15-year-old cohort comprises a significant source of cohort "loss" 173 among C/ALHIV continuing ART for each FY from 2020-2022 and is greater than IIT in both 174 FY2021 and FY2022. Impact of aging-out is not routinely captured in programmatic PEPFAR data 175 and requires individual-level data analysis for identification. In this analysis, impact of aging-out 176 results in CoT estimates that underestimate actual CoT for C/ALHIV. Additionally, C/ALHIV 177 who experienced IIT decreased each FY under study, perhaps due to successful programmatic 178 interventions such as Operation Triple Zero - a customized adolescent-focused service delivery 179 model for "Zero viral load, Zero missed appointments, and Zero missed drugs", implemented 180 around the same timeframe [17].

181

When a C/ALHIV is not retained on ART, understanding IIT root causes allows for tailored CoT interventions that improve clinical outcomes. Programs can then provide targeted support to C/ALHIV on ART who have aged out of the cohort, but remain on treatment, to ensure successful transition to adulthood. Focused, person-centered support is particularly important as demonstrated through a recent systematic review that indicated wide variation (37 to 97.4%) of CoT rates among ALHIV following transition to adult services [18].

188

Based on our analyses that allowed for accurate estimation of CoT, future directions would include analyzing individual-level clinical outcomes among subsets of C/ALHIV who experienced IIT. Analysis of IIT root causes among C/ALHIV at clinical sites will shed light on specific reasons for ART interruption and provide actionable data to optimize program implementation. Additionally, individual-level analyses are needed to verify if adolescents who aged out of

pediatric cohorts (0-14 years) have successfully transitioned to adult cohorts (15+ years). Kenya's
National Unique Patient Identifier program utilizes birth certificate registration numbers to provide
unique identifier numbers to C/ALHIV. Future Kenyan analyses can utilize these identifiers to
deduplicate and track outcomes of C/ALHIV who experience IIT.

198

This analysis has some limitations. Firstly, it excludes Kenyan treatment sites that utilize paper records and sites in seven low-HIV burden counties potentially affecting generalizability of findings. As of Jan 2022, 85% (1,046,761) of all clients on ART were seen at an EMR-site. Secondly, annual analysis may mask short-term trends. And lastly, the study population focuses on those with documented interruptions, omitting transfers and deaths.

204

205 "Aging Out" analyses are now easier to perform - EMRs are more prevalent; access to patient-206 level data has increased; standardized protocols for loss analysis are refined; and PEPFAR 207 guidance is now explicit in calling for these analyses. However, performing these analyses 208 separately for each age-band and implementing partner remains burdensome. Ideally these 209 analyses would be performed through unified host country data systems that house patient-level 210 data reported directly to Ministries of Health (MoH), and MoH partners. This would permit speedy 211 identification of gaps in CoT, adjusting for losses and gains due to normal aging-out. Ultimately, 212 by improving individual-level clinical outcomes for C/ALHIV, these analyses bolster long-term 213 sustainability of host country HIV treatment programs.

## 214 Conclusions

This analysis suggests that normal aging-out results in underestimation of HIV treatment continuity for C/ALHIV. Routine aging-out analyses can inform programs on their true rates of IIT, as they work to achieve epidemic control among C/ALHIV.

# 218 Acknowledgements

We thank Nassir Kashmiri, formerly with Management and Development for Health (MDH),
Tanzania, and Roland Van de Ven, USAID Afya Yangu Northern, Tanzania, for sharing
unpublished data with the study authors, and Ohvia Muraleetharan who worked on the initial
abstract for this paper.

### 223 **References**

- Joint United Nations Programme on HIV/AIDS. UNAIDS Data 2023 [Internet]. 2023 [cited
   2023 Sep 22]. Available from: <u>https://aidsinfo.unaids.org</u>
- UNICEF. Monitoring the situation of children and women [Internet]. 2023 [cited 2023 Oct
   Available from: <u>https://data.unicef.org/topic/hivaids/paediatric-treatment-and-care/</u>
- Govender K, Nyamaruze P, Cowden RG, Pillay Y, Bekker LG. Children and young women in eastern and southern Africa are key to meeting 2030 HIV targets: time to accelerate action. Lancet HIV [Internet]. 2023;10(5):e343–50. Available from: <u>https://www.sciencedirect.com/science/article/pii/S2352301823000127</u>
- Afrane AKA, Goka BQ, Renner L, Yawson AE, Alhassan Y, Owiafe SN, Agyeman S,
   Sagoe KWC, Kwara A. HIV virological non-suppression and its associated factors in
   children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross sectional study. BMC Infect Dis. 2021;21(1):731. doi: 10.1186/s12879-021-06459-z.
   PMID: 34340689; PMCID: PMC8330060.
- 237 5. Tanyi WN, Gachuno O, Odero T, Farquhar C, Kimosop D, Mayi A. Factors affecting

adherence to antiretroviral therapy among children and adolescents living with HIV in the
Mbita Sub-County Hospital, Homa Bay- Kenya. Afr Health Sci. 2021;21(Suppl):18-24. doi:

240 10.4314/ahs.v21i1.4S. PMID: 34447419; PMCID: PMC8367307

- 6. Humphrey JM, Genberg BL, Keter A, Musick B, Apondi E, Gardner A, et al. Viral
  suppression among children and their caregivers living with HIV in Western Kenya. *J Int AIDS Soc.* 2019;22(4):e25272. doi: 10.1002/jia2.25272
- Onyango B, Mokaya R, Wasianga J, Wao H, Achwoka D, Onyango N, Kadengye DT.
   Factors associated with viral load suppression among orphans and vulnerable children and
   adolescents living with HIV in Kenya. PLOS global public health. 2023;3(3), e0000794.
   https://doi.org/10.1371/journal.pgph.0000794
- Teasdale CA, Sogaula N, Yuengling KA, Wang C, Mutiti A, Arpadi S, et al. HIV viral
   suppression and longevity among a cohort of children initiating antiretroviral therapy in
   Eastern Cape, South Africa. J Int AIDS Soc. 2018;21(8):e25168. doi: 10.1002/jia2.25168
- Rosen JG, Muraleetharan O, Walker A, Srivastava M. Pediatric Antiretroviral Therapy
   Coverage and AIDS Deaths in the "Treat All" Era. Pediatrics [Internet]. 2023;151(6).
   Available from: https://doi.org/10.1542/peds.2022-05901
- PEPFAR. PEPFAR Monitoring, Evaluation, and Reporting Indicator Reference Guide:
   MER 2.0 (Version 2.5) [Internet]. 2020 [cited 2023 May 19]. Available from:
   <a href="https://datim.zendesk.com/hc/article\_attachments/360071630231/FY21\_MER\_2.5\_Indicat">https://datim.zendesk.com/hc/article\_attachments/360071630231/FY21\_MER\_2.5\_Indicat</a>
   or Reference Guide.pdf
- PEPFAR. PEPFAR 2021 Country and Regional Operational Plan (COP/ROP) Guidance for
   all PEPFAR Countries [Internet]. 2021 [cited 2023 May 22]. Available from:
   https://www.state.gov/wp-content/uploads/2020/12/PEPFAR-COP21-Guidance-Final.pdf
- PEPFAR. PEPFAR 2022 Country and Regional Operational Plan (COP/ROP) Guidance for
   all PEPFAR-Supported Countries [Internet]. 2022 [cited 2023 May 16]. Available from:
   <u>https://www.state.gov/wp-content/uploads/2022/02/COP22-Guidance-Final\_508-</u>
- 264 <u>Compliant-3.pdf</u>
- 265 13. PEPFAR. PEPFAR FY 2024 Technical Considerations [Internet]. 2023 [cited 2023 May
  266 22]. Available from: <u>https://www.state.gov/wp-content/uploads/2023/02/FY-2024-</u>
  267 PEPFAR-Technical-Considerations.pdf
- 268 14. Stephens JL. Impact of Aging on ART Continuation for Performance Management and

- 269 Target Setting. In: Virtual Conference. CROI; 2021.
- 270 15. Odero L, Muraleetharan O, Simiyu T, Achwoka D, Golin R. How many adolescents do we
  271 actually lose along the HIV treatment cascade?: Accounting for aging up in adolescent
  272 continuity of treatment. In: Virtual Conference [Internet]. International Workshop on HIV
- and Adolescence; 2021. Available from:
   https://academicmedicaleducation.com/meeting/international-workshop-hiv-adolescence 2021/e-poster/how-many-adolescents-do-we-actually
- 16. Ndisha M, Hassan AS, Ngari F, Munene E, Gikura M, Kimutai K, et al. Leveraging
  electronic medical records for HIV testing, care, and treatment programming in Kenya—
  the national data warehouse project. BMC Med Inform Decis Mak [Internet].
  2023;23(1):183. Available from: https://doi.org/10.1186/s12911-023-02265-6
- 17. Centers for Disease Control and Prevention. Operation Triple Zero: Empowering
   Adolescents and Young People living with HIV in Ethiopia [Internet]. CDC; 2021 [cited
   2023 Oct 11]. Available from: <u>https://www.cdc.gov/globalhivtb/who-we-</u>
   are/features/operationtriplezero.html
- 18. Ritchwood TD, Malo V, Jones C, Metzger IW, Atujuna M, Marcus R, et al. Healthcare
  retention and clinical outcomes among adolescents living with HIV after transition from
  pediatric to adult care: a systematic review. BMC Public Health [Internet].
  2020;20(1):1195. Available from: https://doi.org/10.1186/s12889-020-09312-1




Fig 1. Tracking treatment outcomes among C/ALHIV in Kenya - F




Fig 2. Tracking treatment outcomes among C/ALHIV in Kenya - F\




Fig 3. Tracking treatment outcomes among C/ALHIV in Kenya - F